Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxford Biomedica PLC Remuneration Information 2023

Jul 3, 2023

5190_def-14a_2023-07-03_ef53c97f-401d-4dfc-b2eb-0d3323e551a0.html

Remuneration Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information /*<![CDATA[*/ /**/ /**/ /**/ .m{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.m{}table.ai{width:451.3pt;margin-left:-10.8pt;border-collapse:collapse}td.ae{width:210.05pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.aj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;line-height:normal}span.ag{font-size: 10.0pt;font-family:"Arial","sans-serif";color:black}td.ad{width:219.65pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ac{width:210.05pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ab{width:219.65pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aa{width:152.95pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt} td.z{width:46.3pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.y{width:76.85pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.x{width:15.2pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.w{width:106.0pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.v{color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; text-decoration: underline}span.u{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}span.t{font-size:10.0pt; font-family:"Times New Roman","serif";color:black}td.q{padding:0cm 0cm 0cm 0cm}p.ak{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.s{font-size:10.0pt;font-family:"Times New Roman","serif"; color:black} span.p{font-size:10.0pt;font-family:"Times New Roman","serif"}td.n{border:none}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .m{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/

RNS Number : 6510E

Oxford Biomedica PLC

03 July 2023

For Immediate Release                                                                                                                                           3 July 2023****

OXFORD BIOMEDICA PLC

BLOCK LISTING RETURN

Name of applicant: OXFORD BIOMEDICA PLC
Name of scheme: 2015 Employee Share Option Scheme
Period of return: From: 1 January 2023 To: 30 June 2023
Balance of unallotted securities under scheme(s) from previous return: 331,574
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 22,148
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 309,426
Name of applicant: OXFORD BIOMEDICA PLC
Name of scheme: 2015 Long Term Incentive Plan
Period of return: From: 1 January 2023 To: 30 June 2023
Balance of unallotted securities under scheme(s) from previous return: 339,319
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 300,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 196,342
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 442,977
Name of applicant: OXFORD BIOMEDICA PLC
Name of scheme: 2015 Deferred Bonus Plan
Period of return: From: 1 January 2023 To: 30 June 2023
Balance of unallotted securities under scheme(s) from previous return: 202,445
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 100,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 6,173
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 296,272
Name of applicant: OXFORD BIOMEDICA PLC
Name of scheme: Sharesave Scheme
Period of return: From: 1 January 2023 To: 30 June 2023
Balance of unallotted securities under scheme(s) from previous return: 331,484
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 100,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 91,731
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 339,753

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRFLFSRDVIFIIV